TAVI Without Balloon Predilatation (of the Aortic Valve ) SAPIEN 3 (DIRECTAVI)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02729519 |
Recruitment Status :
Completed
First Posted : April 6, 2016
Last Update Posted : October 11, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Aortic Valve Stenosis | Procedure: TAVI | Not Applicable |
Background Transcatheter aortic valve implantation (TAVI) is now the standard of care for inoperable patients with severe symptomatic aortic stenosis and an accepted alternative to surgery for high-risk patients. Despite a high procedure success rate (> 95%), TAVI remained associated with complications directly related to the technique (stroke, aortic regurgitation, vascular access bleeding) or to co morbidities frequently associated with aortic valve disease in elderly and frail patients. Reducing periprocedural complications is thereby the key for the future use of TAVI in lower-risk patients.
Methods/design The transcatheter aortic valve implantation without prior balloon dilatation (DIRECTAVI) trial is a randomized controlled open label trial that include 240 patients randomized to TAVI performed with prior balloon dilatation of the valve (control arm) or direct implantation of the valve (test arm). The trial tests the hypothesis that the strategy of direct implantation of the balloon expandable SAPIEN 3 prosthesis is non-inferior to current medical practice using predilatation of the valve. The primary endpoint is related to immediate procedural success criteria and secondary end points include complications at 30-day follow-up (VARC 2 criteria). A subgroup analysis evaluates neurological ischemic events with cerebral MRI imaging (25 patients in each strategy group) performed before and after the procedure.
In conclusion, we hope that the study will provide robust evidence of safety and efficiency of TAVI performed without prior dilatation of the aortic valve using the balloon expandable SAPIEN 3 THV and will allow the interventional cardiologist to use this strategy in everyday practice.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 250 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Participant) |
Primary Purpose: | Treatment |
Official Title: | Implantation of the Transcatheter Aortic Prosthesis SAPIEN 3 With or Without Prior Balloon Predilatation |
Actual Study Start Date : | June 8, 2016 |
Actual Primary Completion Date : | June 29, 2018 |
Actual Study Completion Date : | August 9, 2018 |

Arm | Intervention/treatment |
---|---|
Group A
standard procedure TAVI performed with systematic pre dilatation (With prior balloon dilatation)
|
Procedure: TAVI
standard procedure TAVI performed with systematic pre dilatation (With prior balloon dilatation) (ARM A) ou without pre dilatation (ARM B) |
Experimental: Groupe B
standard procedure TAVI performed without pre dilatation (Without prior balloon dilatation)
|
Procedure: TAVI
standard procedure TAVI performed with systematic pre dilatation (With prior balloon dilatation) (ARM A) ou without pre dilatation (ARM B) |
- immediate procedural success [ Time Frame: up to 72h ]Composite endpoint : absence of immediate procedural mortality AND correct positioning of a single prosthetic heart valve into the proper anatomical location AND intended performance of the prosthetic heart valve (no prosthesis-patient mismatch and mean aortic valve gradient<20 mm Hg or peak velocity<3 m/s), AND no moderate or severe prosthetic valve regurgitation.
- cardiovascular event [ Time Frame: 1 month ]
- Complications post-procedure [ Time Frame: up to 1 month ]VARC-2 criteria : life-threatening/major/minor bleeding, vascular access complications, heart failure, acute kidney failure (RANKIN classification stage 2 or 3), conduction disturbances, stroke, pacemaker implantation, Repeat procedure for valve-related dysfunction (surgical or interventional therapy)
- neurological ischemic events [ Time Frame: up to 2 days ]Ancillary study : subgroup analysis evaluates neurological ischemic events with cerebral MRI imaging (25 patients in each strategy group) performed before and after the procedure.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Symptomatic Aortic valve stenosis with an aortic valve area <1 cm2 (<0,6 cm3/m2)
- Males or females of at least 18 years of age
- Logistic EuroSCORE ≥15% and/or a significant contraindication for open heart surgery (e.g., porcelain aorta or severe COPD) or all patients considered as having excessive surgical risk by the heart team
- Signed informed consent
- TAVI performed via transfemoral, sub clavicular or transaortic route with the SAPIEN 3 THV (Edwards Lifescience)
Exclusion Criteria:
- Transapical TAVI
- Preexisting aortic prosthesis (valve in valve technique)
- Vascular conditions that make insertion and endovascular access to the aortic valve impossible
- BAV performed for less than one week
- Recent myocardial infarction (STEMI within the last 3 months)
- Left ventricular or atrial thrombus by echocardiography
- Mitral or tricuspidal valvular insufficiency (> grade II)
- Evolutive or recent cerebrovascular event (within the last 3 months)
- Symptomatic carotid or vertebral arterial narrowing (>70%) disease
- Bleeding diathesis or coagulopathy or patient refusing blood transfusion
- Lack of written informed consent, severe mental disorder, drug/alcohol addiction
- Life expectancy < 1 year
- Hypersensitivity or contraindication to acetyl salicyl acid, heparin, ticlopidine, clopidogrel, or sensitivity to contrast media that cannot be adequately premedicated
- Participation in another drug or device study that would jeopardize the appropriate analysis of end-points of this study.
- High probability of non-adherence to the follow-up requirements (due to social, psychological or medical reasons)
- Pregnancy

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02729519
France | |
University hospital of Montpellier | |
Montpellier, France, 34295 |
Principal Investigator: | Florence LECLERCQ, MD,PhD | UH of Montpellier |
Responsible Party: | University Hospital, Montpellier |
ClinicalTrials.gov Identifier: | NCT02729519 |
Other Study ID Numbers: |
9634 |
First Posted: | April 6, 2016 Key Record Dates |
Last Update Posted: | October 11, 2018 |
Last Verified: | October 2018 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Aortic Valve Stenosis Aortic Valve Disease Heart Valve Diseases |
Heart Diseases Cardiovascular Diseases Ventricular Outflow Obstruction |